A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Completed · Phase 2 · Has a placebo group
Conditions studied: Gastric Cancer
In brief
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.
Key facts
- Study ID
- NCT03694522
- Run by
- Five Prime Therapeutics, Inc.
- People needed
- 155
- Starts
- 2018-09-14
- Expected to finish
- 2022-05-13
- Last updated by the study team
- 2024-02-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Oncology Institute of Tuscon — Tucson, Arizona, United States
- Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc — Greenbrae, California, United States
- Sutter Medical Group — Sacramento, California, United States
- UCLA Medical Centre - Santa Monica Hematology and Oncology — Santa Monica, California, United States
- Innovative Clinical Research Institute (ICRI) — Whittier, California, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut — Plainville, Connecticut, United States
- University of Chicago — Chicago, Illinois, United States
- Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois, United States
- University of Kansas Medical Center — Westwood, Kansas, United States
- Oschsner Clinic Foundation — New Orleans, Louisiana, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan Health System — Ann Arbor, Michigan, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Josephine Ford Cancer Center-Henry Ford Cancer Center — Detroit, Michigan, United States
- Summit Medical Group. Morristown Oncology — Morristown, New Jersey, United States
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) — Rochester, New York, United States
- Stony Brook Cancer Center — Stony Brook, New York, United States
- Westchester Institute For Treatment Of Cancer & Blood Disorders — White Plains, New York, United States
- UNC- Chapel Hill — Chapel Hill, North Carolina, United States
- FirstHealth Outpatient Cancer Center — Pinehurst, North Carolina, United States
- St. Luke's Physician Group - St. Luke's Cancer Care Associates — Bethlehem, Pennsylvania, United States
- Medical University of South Carolina — Charleston, South Carolina, United States
- University of Arizona Cancer Center — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.